proven lymphoma site had an SUV of 16.2 ( Figure 1C) . Thus, the patient was diagnosed with stage IIIB DLBCL with a low-to intermediate-risk international prognostic indicator score.
The patient was started on Atripla (efavirenz, emtricitabine, tenofovir; Bristol-Myers Squibb/Gilead Sciences), Bactrim (trimethoprim and sulfamethoxazole; Roche), and fluconazole, and was scheduled to start immuno/chemotherapy immediately. The patient deferred therapy for approximately 6 weeks, during which time his CD4 count rose to 264 mm 3 , his viral load fell to 2880 copies/mL, and complete clinical resolution of his lymphadenopathy occurred. Repeat PET/CT scan confirmed the dramatic resolution of his adenopathy; for example, an axillary lymph node measuring 5 cm with SUV of 15 measured 3.6 cm with SUV of 4.7 after HAART. The biopsy proven right cervical lymph node decreased from 3.7 cm to 1.2 cm with a decrease in SUV from 16 to 6 ( Figure 1D ). The patient was scheduled for chemotherapy as initially planned.
We have thus observed a dramatic clinical improvement of DLBCL to 6 weeks of HAART alone. Although PET scans may be positive in patients with benign HIV-related lymphadenopathy, typically there is minimal uptake in the absence of infections. There was no evidence that our patient had any infectious diseases that caused increased uptake. Although we cannot confirm that all PET-positive sites contained lymphoma, the site of biopsydocumented disease also demonstrated dramatic clinical and PET improvement after initiation of HAART.
The role that HIV plays in DLBCL is unclear. In contrast to case reports demonstrating improvement with HAART alone in MALT and effusion lymphoma, there are no data that suggest DLBCL is driven by infectious antigenic stimuli. The high incidence of DLBCL in immunosuppressed states, as well as data from allogeneic transplantation, suggest a role for immunosurveillance in this 
